These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9513400)

  • 1. [Lewis antigens and CA19-9].
    Naka K; Shimojo N
    Nihon Rinsho; 1998 Jan; 56 Suppl 3():117-20. PubMed ID: 9513400
    [No Abstract]   [Full Text] [Related]  

  • 2. [2-->6 Sialyl Le(a) antigen].
    Miyazaki K; Kannagi R
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():663-8. PubMed ID: 16149606
    [No Abstract]   [Full Text] [Related]  

  • 3. [CA50].
    Kawabe T
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():645-6. PubMed ID: 16149601
    [No Abstract]   [Full Text] [Related]  

  • 4. CA19-9: the Italian experience.
    Gullo L
    Pancreas; 1994 Nov; 9(6):717-9. PubMed ID: 7846014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CA19-9].
    Odagiri E
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():642-4. PubMed ID: 16149600
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical significance of Lewis blood-group phenotype and serum CA-19-9 analysis in the diagnosis of diabetic diseases].
    Shimojo N; Okuda K
    Nihon Rinsho; 1990 Dec; 48 Suppl():359-64. PubMed ID: 2086909
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
    Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
    Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum CA19-9 determination in the management of pancreatic cancer.
    van den Bosch RP; van Eijck CH; Mulder PG; Jeekel J
    Hepatogastroenterology; 1996; 43(9):710-3. PubMed ID: 8799418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of latex photometric immunoassay for serum CA19-9].
    Eda S; Miyake K; Horii T; Igari J
    Rinsho Byori; 1995 Mar; 43(3):257-62. PubMed ID: 7745831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA 19-9 and Lewis antigens in pancreatic cancer.
    Atkins CD
    J Clin Oncol; 2009 May; 27(15):2572-3; author reply 2573. PubMed ID: 19380435
    [No Abstract]   [Full Text] [Related]  

  • 12. Pancreatic cancer.
    Go VL
    Pancreas; 1994 Nov; 9(6):673. PubMed ID: 7846009
    [No Abstract]   [Full Text] [Related]  

  • 13. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum determination of CA 19-9 in diagnosing pancreatic cancer: an obituary.
    Pezzilli R; Casadei R; Calculli L; Santini D; Morselli-Labate AM;
    Dig Liver Dis; 2010 Jan; 42(1):73-4. PubMed ID: 19473891
    [No Abstract]   [Full Text] [Related]  

  • 15. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-Hodgkin's lymphoma of the pancreas with elevated serum CA 19-9 and SPAN-1].
    Ohta T; Hirai M; Kishida T; Tatsumi N
    Rinsho Ketsueki; 1998 Aug; 39(8):611-3. PubMed ID: 9785981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
    Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
    Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
    Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
    Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CA19-9 has no value as a tumor marker in obstructive jaundice].
    Peterli R; Meyer-Wyss B; Herzog U; Tondelli P
    Schweiz Med Wochenschr; 1999 Jan; 129(3):77-9. PubMed ID: 10065510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.